查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405793

高雪氏症治療藥物市場規模、佔有率、趨勢分析報告：按類型、治療、按地區、細分市場預測，2023-2030 年

Gaucher Disease Drugs Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2, Type 3, Others) By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 84 Pages | 商品交期: 2-10個工作天內

價格

高雪氏症治療藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2023年至2030年全球高雪氏症治療市場規模將以2.6%的複合年成長率成長，2030年達到20.3億美元。

該疾病盛行率的上升以及該領域研究和開發活動的活性化可能有助於推動未來幾年的市場發展。鑑於大量未滿足的需求，迫切需要開發新的治療方法提高療效、簡化給藥並降低神經毒性併發症的成本。

高雪氏症是一種由 GBA 基因突變引起的遺傳性代謝疾病。高雪氏症的人產生的Glucocerebrosidase(GCase) 較少，而葡萄糖腦苷脂酶是分解Glucocerebroside所需的酵素。過多的脂質積聚在脾、肝、腎、腦、肺和骨髓中，干擾器官的正常功能。

儘管高雪氏症是最常見的溶小體貯積症，但它是一種罕見疾病，平均盛行率為十萬分之一。然而，某些種族群體，例如德系猶太人，更容易感染這種疾病。德系猶太人的平均盛行率為五百分之一。

目前，最常見的高雪氏症類型是第 1 型。此疾病本質上是非神經病變的，因為它不影響中樞神經系統(CNS)。 2017年1型GD佔市佔率超過75.0%。預計這一地位將維持到2025年。類型 2 和類型 3 不如類型 1 常見。

從治療方法來看，酵素替代療法（ERT）是2017年市場收益的主要貢獻者。該領域的成長是由 Cerezyme 和 Vpriv 的強勁銷售推動的。然而，在 Cerdelga 和 Zavesca 的帶領下，基材替代療法 (SRT) 的趨勢日益明顯。 ERT 主要適用於 1 型和 3 型（解決與中樞神經系統無關的問題），因為補充酶無法穿過血腦障壁。此外，2型沒有有效的治療方法。

高雪氏症治療藥物市場報告亮點

  • 2型是三種GD中最罕見的一種，平均死亡率不到2年。
  • 以賽諾菲健贊 (Sanofi Genzyme) 的 Cerezyme 為代表的酵素替代療法是治療的支柱。然而，GD 治療正在轉向基材替代療法。
  • 美國在銷售和疾病負擔方面均領先主要市場。由於患者基礎不斷擴大且獲得治療的便利性，預計該國將在 2030 年之前繼續主導市場。
  • 進入該市場的知名公司包括賽諾菲健贊 (Sanofi Genzyme)、夏爾 (Shire)、輝瑞 (Pfizer) 和強生 (Johnson & Johnson)。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章高雪氏症治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 高雪氏症治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章高雪氏症治療藥物：類型估計與趨勢分析

  • 高雪氏症症藥物市場：要點
  • 高雪氏症治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 類型1
  • 2型
  • 類型3
  • 其他

第5章高雪氏症治療藥物：治療估計與趨勢分析

  • 高雪氏症症藥物市場：要點
  • 高雪氏症治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 酵素替代療法
  • 基材交換療法
  • 其他

第6章高雪氏症治療藥物市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的高雪氏症治療藥物市場：主要市場點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc
    • Johnson & Johnson Services, Inc.
    • ERAD Therapeutic
Product Code: GVR-2-68038-599-1

Gaucher Disease Drugs Market Growth & Trends:

The global gaucher disease drugs market size is expected to reach USD 2.03 billion by 2030, expanding at a CAGR of 2.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for the development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to the strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

Gaucher Disease Drugs Market Report Highlights:

  • Type 2 is the rarest of the three forms of GD, with an average mortality rate of less than two years
  • Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme's Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy
  • The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2030, on account of widening the patient base and easy accessibility to treatments
  • Some of the prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Therapy
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Therapy outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Gaucher Disease Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Gaucher Disease Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Gaucher Disease Drugs: Type Estimates & Trend Analysis

  • 4.1. Gaucher Disease Drugs Market: Key Takeaways
  • 4.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Type 1
    • 4.3.1. Type 1 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Type 2
    • 4.4.1. Type 2 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Type 3
    • 4.5.1. Type 3 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Gaucher Disease Drugs: Therapy Estimates & Trend Analysis

  • 5.1. Gaucher Disease Drugs Market: Key Takeaways
  • 5.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Enzyme Replacement Therapy
    • 5.3.1. Enzyme replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Substrate Replacement Therapy
    • 5.4.1. Substrate replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Gaucher Disease Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Gaucher Disease Drugs Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Sanofi
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Takeda Pharmaceutical Company Limited
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Pfizer Inc
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Johnson & Johnson Services, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. ERAD Therapeutic
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 3 North America Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 North America Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 Canada Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 9 Europe Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 10 Europe Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 Europe Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 UK Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 13 UK Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 Germany Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 15 Germany Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 16 France Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 17 France Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 18 Italy Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 19 Italy Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 20 Spain Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 21 Spain Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 Sweden Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 23 Sweden Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 24 Norway Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 25 Norway Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 26 Denmark Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 27 Denmark Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 32 China Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 33 Japan Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 35 India Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 36 India Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 37 Australia Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 38 Australia Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 39 Thailand Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 40 Thailand Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 41 South Korea Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 42 South Korea Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 43 Latin America Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 45 Latin America Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 47 Brazil Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 48 Mexico Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 49 Mexico Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 50 Argentina Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 51 Argentina Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 57 South Africa Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 58 South Africa Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 59 UAE Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 60 UAE Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Gaucher disease drugs: Market outlook
  • Fig. 9 Gaucher disease drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Gaucher disease drugs market driver impact
  • Fig. 15 Gaucher disease drugs market restraint impact
  • Fig. 16 Gaucher disease drugs market strategic initiatives analysis
  • Fig. 17 Gaucher disease drugs market: Type movement analysis
  • Fig. 18 Gaucher disease drugs market: Type outlook and key takeaways
  • Fig. 19 Type 1 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Type 2 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Type 3 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Gaucher disease drugs market: Therapy movement analysis
  • Fig. 24 Gaucher disease drugs market: Therapy outlook and key takeaways
  • Fig. 25 Enzyme replacement therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Substrate replacement therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Global gaucher disease drugs market: Regional movement analysis
  • Fig. 29 Global gaucher disease drugs market: Regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)